Zekiye HASBEK, Seyit Ahmet ERTÜRK, Ali ÇAKMAKCILAR, Tuba ÇANDAR, Gülhan DUMAN

SERUM GALEKTİN-3 VE DİFERANSİYE TİROİD KANSER İLİŞKİSİ

Amaç: Diferensiye tioid kanserli (DTK) hastalarda total tioidektomi sonrası risk skorlamasına göre verilenI-131 (radyoiyot) ile ablasyon, tüm dünyada ve ülkemizde sıklıkla kullanılan bir tedavi yöntemidir. Kansergelişimindeki rolü açıklanamamakla birlikte, Galekti-3’ün artmış ekspresyonunun tümör hücrelerinin adhezyon ve motiitelerini değiştierek metastaz potansiyelini artıdıkları bildirilmektedir. Araştımalara göreGalekti-3 (Gal-3) özellikle papiller tioid kanserlerinde olmak üzere DTK’da pozititr.Bu çalışmada amacımız, DTK nedeniyle total tioidektomili, ardından yüksek doz radyoiyot ablasyon tedavisialma amacı olan hastalarda ölçülen serum Galekti-3 (sGal-3) seviyelerinin, hastaların tüm vücut taramasintirafieri ile değerlendirilerek prognosti ilişkisinin varlığının araştıılmasıdır.Gereç ve Yöntem: sGal-3 seviyeleri Abbot i sistem otoanalizörde çalışıldı. İyi prognoz göstergesi ve ablasyonbaşarısı; TSH stiüle durumda iken, serum Tg seviyeleri ölçülemeyecek kadar düşük düzeyde (stiüle Tg

The Relatin Between Serum Galecti-3 and Diffrentil Thyroid Cancers

Aim: I-131 (radioiodine) ablatin following total thyroidectomy in patints with diffrentil thyroid cancer (DTC) is a routie treatment method. Increased expression of Galecti-3 in tumor cells has been shown to alter adhesion and motiity resultig with increased metastati potentil although its role in cancer development has not been demonstrated yet. Galecti-3 (Gal-3) was declared positie in DTC, especially in papillary thyroid carcinomas. The aim of study is to investiate whether there is a prognosti associatin between serum Galecti-3 levels measured in patints with total thyroidectomy due to DTC, followed by high-dose radioiodine ablatin therapy and whole body screening scintiraphy. Materials and Methods: sGal-3 levels were studied in the Abbot i system autoanalyzer. Success of ablatin and good prognosis were defied via too low Tg levels under TSH stiulatin, normal physical examinatin fidings and/or post-ablatin negatie low dose whole body radioiodine scintiraphy 8 to 12 months aftr ablatin, absence of any fidings suggestig lymph node and distant metastasis in radiological or clinical evaluatin. Findings: Forty-eight patints were included in the study. sGal-3 levels were within the normal range in whole patints of whom two had values close to upper limit. Immunohistochemically, Galecti-3 was positie in 25 of the patints, whereas negatie in other 23. There was no correlatin between immunohistochemically evaluated levels of Gal-3 and sGal-3 (p = 0.663). The relatinship between ablatin success and sGal-3 was not statitially signifiant (p> 0.05). Conclusion: There was no signifiant relatinship between ablatin success and sGal-3. A possible explanatin for this result might be excretin of sGal-3 from the tumor tisue and absence of tumour tisue at the tie of sampling for sGal-3 in the study populatin. In conclusion, the authors suggest that sGal-3 is a good prognosti indicator when it is at normal levels during ablatin.

PDF

___

1. R. Görges. The Changing Epidemiology of Thyroid Cancer. In: H.-J. Biersack F. Grünwald, Eds. Thyroid Cancer. Springer Science+Business Media, Germany, 2005.p:3-21.
2. Fernández PL, Merino MJ, Gómez M, Campo E, Medina T, Castronovo V, Sanjuán X, Cardesa A, Liu FT, Sobel ME. Galecti-3 and laminin expression in neoplasti and non-neoplasti thyroid tisue. J Pathol. 1997;181(1):80-6.
3. Liu Z, Li X, Shi L, Maimait Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W, Huang T. Cytokerati 19, thyroperoxidase, HBME-1 and Galecti-3 in evaluatin of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med. 2014,15;7(8):2304-8.
4. Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S. Immunostaining of Galecti-3 and CD44v6 using fie-needle aspiratin for distiguishing follicular carcinoma from adenoma. Diagn Cytopathol. 2004;31(6):392-6.
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuf KG, Sherman SI, Sosa JA, Steward DL, Tutte RM, Wartofsky L. 2015 American Thyroid Associatin Management Guidelines for Adult Patints with Thyroid Nodules and Diffrentited Thyroid Cancer: The American Thyroid Associatin Guidelines Task Force on Thyroid Nodules and Diffrentited Thyroid Cancer. Thyroid. 2016;26(1):1-133.
6. Yılmaz E, Karşıdağ T, Tatar C, Tüzün S. Serum Galecti-3: diagnosti value for papillary thyroid carcinoma. Ulus Cerrahi Derg. 2015, 9;31(4):192-6.
7. Kovács RB, Földes J, Winkler G, Bodó M, Sápi Z. The investiatin of Galecti-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003;149(5):449-53.
8. Al-Sharaky DR, Younes SF. Sensitiity and Specifiity of Galecti-3 and Glypican-3 in Follicular-Pattrned and Other Thyroid Neoplasms. J Clin Diagn Res. 2016;10(3):EC06-10.
9. Selemetjev SA, Savin SB, Paunovic IR, Tati SB, Cvejic D. Changes in the expression pattrn of apoptoti molecules (Galecti-3, Bcl-2,Bax, survivin) during progression of thyroid malignancy and their clinical signifiance. Wien Klin Wochenschr. 2015;127(9-10):337-44.
10. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D. Galecti-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol. 2008;19(2):92-6.
11. Koo JS, Shin E, Hong SW. Immunohistochemical characteristis ofdiffse sclerosing variant of papillary carcinoma: comparison with con-ventinal papillary carcinoma. Acta Pathol, Microbiol Immunol Scand. 2010;118:744–52.
12. Inohara H, Segawa T, Miyauchi A, Yoshii T, Nakahara S, Raz A, Maeda M, Miyoshi E, Kinoshita N, Yoshida H, Furukawa M, Takenaka Y, Takamura Y, Ito Y, Taniguchi N. Cytoplasmic and serum Galecti-3 in diagnosis of thyroid malignancies. Biochem Biophys Res Commun. 2008, 21;376(3):605-10.
13. Xue G, Liu J, Huang J, Zhang J, Zhang W, Wu J, Shang X. Detectin of Galecti-3 in both serum and tisue for early diagnosis of thyroid carcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 2013;33(7):1027-30.
14. Makki FM, Taylor SM, Shahnavaz A, Leslie A, Gallant J, Douglas S, Teh E, Trites J, Bullock M, Inglis K, Pinto DM, Hart RD. Serum biomarkers of papillary thyroid cancer. J Otolaryngol Head Neck Surg. 2013, 7;42:16.
15. Išić T, Savin S, Cvejić D, Marečko I, Tati S, Havelka M, Paunović I. Serum Cyfra 21.1 and Galecti-3 protein levels in relatin to immunohistochemical cytokerati 19 and Galecti-3 expression in patints with thyroid tumors. J Cancer Res Clin Oncol. 2010;136(12):1805-12.